Analysis of the relationship between ultrasound indexes and metabolism indexes in obese patients with polycystic ovary syndrome.

doi:10.3877/cma.j.issn.2095-9605.2021.04.005

Abstract

Abstract:

Objective

To explore the correlation between ultrasound indexes and metabolism-related indexes in obese patients with polycystic ovary syndrome.

Methods

A total of 42 patients with obese polycystic ovary syndrome admitted to our hospital from January 2020 to June 2021 were selected as the observation group. At the same time, 42 patients with basic temperature bipolar infertility were selected as the control group. Follicle number (FN) and ovarian stroma area (OSA), ovarian total area (OTA), uterine artery resistance index (UARI), total ovarian stromal artery resistance index (OARI), and follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), fasting plasma glucose (FPG), fasting insulin (FINS), total cholesterol (TC), triglyceride (TG), low and high-density lipoprotein cholesterol (LDL-C and HDL-C) were measured. The correlation between ultrasonic and metabolic indicators was performed by Person correlation analysis.

Results

Ultrasound indexes such as FN、OSA、OTA、UARI in the observation group were higher than the control group, while the OARI was lower than the control group (P<0.05). Endocrine and metabolic indicators, such as FSH、LH、T、FPG、FINS、TC、TG and LDL-C were higher than in control group (P<0.05). The FN and OSA were positively correlated with T in obese patients with polycystic ovary syndrome, while the OARI was negatively correlated with FPG and FINS (P<0.05).

Conclusions

Ultrasound indicators such as FN, OSA, OTA, and UARI in obese patients with polycystic ovary syndrome increased significantly, and FN, OSA were positively correlated with metabolic index T, and OARI was negatively correlated with FPG and FINS.

Key words: Obesity, Polycystic ovary syndrome, Metabolism, Ultrasonic

Yuyi Hu, Xumin Xie, Yanqing Liu. Analysis of the relationship between ultrasound indexes and metabolism indexes in obese patients with polycystic ovary syndrome.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2021, 07(04): 245-249.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2021.04.005

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2021/V07/I04/245

Figures/Tables 4

References 19

[1]	寇丽辉, 侯丽辉, 孟小钰, 等. 300例糖尿病家族史多囊卵巢综合征患者的临床特征分析 [J]. 实用妇产科杂志, 2018, 34(11): 864-867.
[2]	杨华, 陈缘, 董志勇. 中国肥胖代谢外科数据库: 2020年度报告 [J/CD]. 中华肥胖与代谢病电子杂志, 2021, 7(1): 1-7.
[3]	中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 中国肥胖及2型糖尿病外科治疗指南(2019版) [J]. 中国实用外科杂志, 2019, 39(4): 301-306.
[4]	陈园. 卵巢形态学的超声参数在多囊卵巢综合征诊断中的价值研究 [J]. 当代医学, 2018, 24(22): 143-144.
[5]	楼雪勇,刘艳芬.代谢综合征与基因多态性研究进展 [J]. 中外医学研究, 2019, 17(3): 175-177.
[6]	Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome [J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2006, 20(2): 193-205.
[7]	The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J]. Hum Reprod, 2004, 19(1): 41-47.
[8]	Hellas C, Luca C, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists [J]. Journal of Clinical Endocrinology & Metabolism, 2020, 105(8): e2695-e2709.
[9]	陈慧, 詹维伟, 杨志芳, 等. 伴或不伴胰岛素抵抗的多囊卵巢综合征的超声特征及其与内分泌指标的相关性 [J]. 中国医学影像技术, 2014, 30(4): 5.
[10]	黄文艳. 胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱的效果 [J]. 中国当代医药, 2019, 26(10): 3.
[11]	戴蓓蓓, 任芸芸, 孙莉, 等. 不同表现多囊卵巢综合征超声参数与内分泌指标的相关性研究 [J]. 中华超声影像学杂志, 2014, 23(7): 609-613.
[12]	袁浩, 牛志宏. 多囊卵巢综合征合并代谢综合征患者卵巢颗粒细胞瘦素启动子甲基化的研究 [J]. 上海交通大学学报:医学版, 2018, 38(11): 6.
[13]	Fauser B, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group [J]. Fertility & Sterility, 2012, 97(1): 28-38. e25.
[14]	Sonya K, Wells G A, Zev R. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome[J]. Human Reproduction, 2004(11): 2474-2483.
[15]	Metwally Mostafa et al. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence [J]. Fertility and sterility, 2008, 90(3) : 714-726.
[16]	黄上嘉, 董志勇, 张俊昌, 等. 肥胖与代谢病的多学科综合治疗 [J/CD]. 中华肥胖与代谢病电子杂志, 2018, 4(3): 164-167.
[17]	武红琴, Wallwiener Diethelm, Mueck Alfred O., 等. 多囊卵巢综合征患者合并代谢综合征的患病率和预测指标 [J]. 首都医科大学学报, 2015, 36(4): 553-558.
[18]	陈慧, 詹维伟, 杨志芳, 等. 伴或不伴胰岛素抵抗的多囊卵巢综合征的超声特征及其与内分泌指标的相关性 [J]. 中国医学影像技术, 2014, 30(4): 595-599.
[19]	张芳, 张周龙. 三维能量多普勒超声和内分泌指标在多囊卵巢综合征诊断中的应用 [J].中国超声医学杂志, 2019, 35(10): 935-939.

组别	病例数	FN（个）	OSA（cm²）	OTA（cm²）	UARI	OARI
观察组	42	11.4±0.5	1.43±0.32	5.26±1.53	2.78±0.05	0.75±0.04
对照组	42	6.5±0.4	0.67±0.04	2.51±1.12	2.05±0.03	1.52±0.16
t值	—	81.237	25.638	13.254	93.512	96.235
P值	—	<0.001	<0.001	<0.001	<0.001	<0.001

组别	病例数	FN（个）	OSA（cm²）	OTA（cm²）	UARI	OARI
观察组	42	11.4±0.5	1.43±0.32	5.26±1.53	2.78±0.05	0.75±0.04
对照组	42	6.5±0.4	0.67±0.04	2.51±1.12	2.05±0.03	1.52±0.16
t值	—	81.237	25.638	13.254	93.512	96.235
P值	—	<0.001	<0.001	<0.001	<0.001	<0.001

组别	病例数	FSH	LH	T
观察组	42	5.06±0.45	13.21±4.32	0.78±0.35
对照组	42	4.65±0.53	7.25±2.65	0.55±0.31
t值	—	15.31	7.235	3.21
P值	—	<0.001	<0.001	<0.05

组别	病例数	FSH	LH	T
观察组	42	5.06±0.45	13.21±4.32	0.78±0.35
对照组	42	4.65±0.53	7.25±2.65	0.55±0.31
t值	—	15.31	7.235	3.21
P值	—	<0.001	<0.001	<0.05

组别	病例数	FPG（mmol/L）	FINS（μIU/mL）	TC（mmol/L）	TG（mmol/L）	LDL-C（mmol/L）	HDL-C（mmol/L）
观察组	42	5.63±1.12	25.9±9.38	3.98±1.48	1.95±1.05	2.65±0.69	1.03±0.32
对照组	42	4.98±0.98	12.93±6.01	3.01±1.05	0.96±0.18	2.01±0.32	1.67±0.75
t值	—	3.582	8.025	4.024	11.015	4.589	5.324
P值	—	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export